Allantoin

1. INCI & CAS

INCI: Allantoin · CAS: 97-59-6

2. Role in the formula

Allantoin is used around 0.1–0.5% in cosmetic leave-ons. This bulk listing does not by itself make an OTC skin-protectant claim.

3. Typical use levels (formulation guide)

• Creams, gels and washes: 0.1–0.5% in this reference.

Dissolve into warm water. It recrystallises if the level is too high for the solvent.

4. Regulatory sources & global compliance

• Use CosIng's information on Allantoin as a reference, then verify the specific grade and intended use under market rules.
• EU market placement under Regulation (EC) No 1223/2009 requires a safety review of the finished cosmetic in which Allantoin is used before the cosmetic is placed on the EU market.
• Use the supplier TDS to confirm grade-specific details for Allantoin and review the destination market's requirements.

5. Safety & risk assessment

This level is a cosmetic-formulation guide; the listed level does not itself confer drug or OTC status while finished-product patch and stability testing remain necessary.

6. Stability & packaging

Hold the bulk material in a sealed, cool place shielded from light; for oxidation-sensitive formulas, consider an airless or pump pack; confirm compatibility and stability using the selected formula and pack.

7. Claims language (Do / Don’t)

• The formulation note describes Allantoin as part of a cosmetic direction focused on low-dose allantoin.

• This product entry does not support drug-treatment outcomes, clinical cures, or certifications not documented for the SKU.
• The available details for Allantoin should not be cited in support of whitening, acne treatment, antiperspirant action, sunscreen use, or hair-growth outcomes.

1. INCI & CAS

INCI: Glycerin · CAS: 56-81-5

2. Role in the formula

The glycerin note covers its polyol-humectant role in washes, gels, and emulsions and gives a formulation guide level.

3. Typical use levels (formulation guide)

• The gels and serums use-level reference is 3–8% in this reference.
• For creams, the reference gives 2–5%.
• Rinse-off: 2–4% in this reference.

The water phase is the addition point for Glycerin; a separate melt is unnecessary.

4. Regulatory sources & global compliance

• Treat any CosIng entry for Glycerin as a reference only; verify the grade and intended use under current market rules.
• Regulation (EC) No 1223/2009 requires the final cosmetic with Glycerin to undergo a safety assessment at the level of the finished cosmetic product.
• Use the supplier TDS to confirm grade-specific details for Glycerin and review the destination market's requirements.

5. Safety & risk assessment

The stated concentration is a cosmetic-development reference; it should not be read as a drug authorization or OTC listing with patch and stability testing still needed for the completed formula.

6. Stability & packaging

Store the bulk in a closed container in a cool, shaded place; choose a package with oxidation sensitivity in view; use batch testing to verify stability and package compatibility.

7. Claims language (Do / Don’t)

• The cosmetic formulation concept for Glycerin centers on humectant function.

• The formulation note does not support drug effects, cures, or certification claims that go beyond the documented ingredient information.
• The formulation record for Glycerin should not be used to substantiate a whitening effect, acne treatment, perspiration control, sun protection, or hair growth.

1. INCI & CAS

INCI: Squalane · CAS: 111-01-3

2. Role in the formula

Squalane provides the referenced hydrocarbon-emollient role in a plant-derived grade; mineral oil is not part of this guide.

3. Typical use levels (formulation guide)

• The formulation record indicates 2–6% for gel-creams in this reference.
• The guide range for dry oils is 10–30% in this reference.
• For balms, the reference gives 5–15%.

Use the oil phase to introduce Squalane; a high-shear wax stage is not specified.

4. Regulatory sources & global compliance

• The CosIng record for Squalane, where listed, is informational rather than product-specific authorization.
• EU market placement under Regulation (EC) No 1223/2009 requires the completed product containing Squalane to receive its own safety assessment in the final product context.
• Confirm the received Squalane grade against supplier documentation, then verify the intended market's filing requirements.

5. Safety & risk assessment

This formulation note gives a cosmetic-use reference level; it should not be read as a drug authorization or OTC listing and the finished formula still needs patch and stability testing.

6. Stability & packaging

For bulk storage, avoid warmth and direct sun and keep the container closed; consider an airless or pump format when oxidation sensitivity warrants it; verify the chosen pack against the tested formula.

7. Claims language (Do / Don’t)

• The cosmetic formulation concept for Squalane centers on a light-emollient role.

• This ingredient reference cannot substantiate therapeutic effects, curative outcomes, or unsupported certification statements.
• The formulation record for Squalane does not establish a whitening result, acne-treatment effect, antiperspirant use, sunscreen performance, or hair growth.